13F Holdings
中文EN

EQ Equillium, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1746466 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.9%
TTM net income YoY39.5%
TTM EPS YoY39.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-20.1%
Net margin-19.6%
FCF margin-46.5%
EBITDA margin-19.8%

Returns

ROE-38.8%
ROA-21.2%
ROIC (approx.)-3,923.0%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.36x
Accruals ratio28.8%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$41.09M$36.08M$15.76M—
R&D expense$12.84M$37.43M$37.04M$37.55M$26.38M
SG&A expense$10.79M$11.94M$13.57M$17.24M$11.41M
Operating income-$23.63M-$8.27M-$14.52M-$62.08M-$37.79M
Interest expense——$491,000$1.05M$1.07M
Pretax income-$22.40M-$7.71M-$12.76M-$62.43M-$39.05M
Income tax$0$361,000$580,000$0$0
Net income-$22.40M-$8.07M-$13.34M-$62.43M-$39.05M
EBITDA-$23.52M-$8.13M-$14.40M-$61.96M-$37.71M
EPS (basic)-0.39-0.23-0.38-1.85-1.36
EPS (diluted)-0.39-0.23-0.38-1.85-1.36
Weighted avg. shares (diluted)57.30M35.36M34.73M33.73M28.81M
Balance sheet
Cash & equivalents$30.28M$18.09M$23.22M$59.11M$50.37M
Short-term investments—$4.49M$17.65M$11.92M$30.34M
Receivables—$0$3.73M$2.84M$0
Current assets$31.04M$24.98M$49.35M$76.73M$83.37M
PP&E, net$164,000$262,000$315,000$391,000$237,000
Total assets$31.89M$25.60M$50.53M$78.42M$85.41M
Current liabilities$2.93M$6.36M$27.57M$32.04M$8.91M
Short-term debt———$5.71M$1.43M
Long-term debt———$3.24M$8.75M
Total debt———$8.95M$10.18M
Total liabilities$3.29M$6.54M$27.96M$46.48M$18.90M
Shareholders' equity$28.60M$19.06M$22.57M$31.94M$66.50M
Net debt———-$50.15M-$40.19M
Shares outstanding61.46M35.56M35.25M34.41M29.46M
Cash flow statement
Operating cash flow-$22.75M-$19.03M-$21.78M-$8.73M-$32.08M
Capital expenditure$48,000$85,000$50,000$279,000$57,000
Free cash flow-$22.79M-$19.11M-$21.83M-$9.01M-$32.14M
Investing cash flow$4.46M$13.81M-$4.76M$18.68M$27.41M
Financing cash flow$30.43M$164,000-$9.23M-$1.22M$31.06M
Depreciation & amortization$116,000$137,000$126,000$118,000$72,000
Stock-based compensation$2.32M$3.75M$4.00M$4.84M$4.41M
Share buybacks——$260,000——

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.